Paris, July 5, 2011—One of the world’s leading public health establishments, AP-HP (Assistance Publique-Hôpitaux de Paris) generated EUR 17 million in revenues thanks to its technology transfer arm, OTTLIV, in 2010. OTTLIV (Office of Technology Transfer, Licensing and Industrial Ventures), a small team of professionals, raised income from license fees, royalties and collaborative research projects.
AP-HP brings together 37 Paris hospitals, including university and teaching establishments, and enjoys close associations with world-famous bodies such as Inserm, the CNRS, the Institut Curie, the Institut Gustav Roussy, the Institut Pasteur, and France’s nuclear energy agency (CEA).
OTTLIV’s mission is to generate the maximum return on AP-HP’s intellectual property and is the single-point of entry for industry to access AP-HP’s IP. It also helps would-be entrepreneurs from AP-HP create their own companies. Last year, it helped establish five new startups, adding to the 35 already in business, and bringing the number of jobs created to 250 in the Paris region.
The 2010 results were revealed last month at OTTLIV’s annual medical innovation conference, APinnov, where it welcomed a number of American senior healthcare representatives interested in OTTLIV’s unique approach. OTTLIV differs from most technology transfer units in focusing on innovations emanating directly from the hospital environment, as well as from universities, and on bringing to market products and services for the greater benefit of the patient, whether developed by researchers in the lab, by clinicians, by nursing staff at the bedside or by others involved in the wide-ranging activities conducted under the auspices of AP-HP.
The 201 requests for technology transfer assistance handled by OTTLIV in 2010 were a new record for the body, which was created in 1992. They included 42 patent applications, nine requests for software protection and 127 projects for partnerships with industry.
“It is really satisfying to see OTTLIV’s efforts to protect and leverage the innovations produced by AP-HP’s doctors and carers bringing results and generating revenues,” said Dr Florence Ghrenassia, OTTLIV director. “We are already intensifying our efforts in industry collaboration and hope to be able to at least maintain these results in 2011.”
About OTTLIV
The Office of Technology Transfer, Licensing and Industrial Ventures protects and leverages innovations produced by patient care and by clinical, laboratory and other research carried out by the Paris public health hospitals, Assistance Publique - Hôpitaux de Paris. OTTLIV benefits from AP-HP’s massive resources. AP-HP is the leading sponsor of clinical trials in Europe and employs 17,000 doctors and pharmacists out of a total of 90,000. 900 of these are directly involved in clinical trials.
OTTLIV provides energetic support to inventors and those with special know-how, and sets up privileged partnerships with French or international companies in the healthcare and biotechnology industries and with other research organizations. The aim is to create the optimal conditions for a collaboration that starts with an innovative concept and ends with bringing to market a product or service that will ultimately benefit the patient.
It organizes the annual APinnov conference in June which brings together key players and those involved in the transfer of medical technologies. It also regularly attends the US BIO conference.
The AP-HP holds 418 patent families, is involved in 685 R&D partnerships and has granted some 150 licenses concerning innovative projects. It continues through OTTLIV to leverage its partnerships with industry. OTTLIV’s work brings more than EUR 15 million to the AP-HP itself, the other two million going to inventors.
OTTLIV’s French name is OTT&PI (Office du Transfert de Technologies et des Partenariats Industriels de l’Assistance Publique - Hôpitaux de Paris).
Mark Tidmarsh
ANDREW LLOYD & ASSOCIATES
http://www.ala.com
mark@ala.com
Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND
Tel: +44 1273 675100
Fax: +44 1273 675400
55 rue Boissonade 75014 Paris FRANCE
Tel: +33 1 56 54 07 00
Fax: +33 1 56 54 07 01
INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION
